top of page
Biosciences
Offspring
Insights & Updates
De-Risking Synucleinopathy Therapeutics: A Human Tissue-First Framework for Target Validation
The transition from preclinical promise to clinical efficacy, the so-called "Translational Gap", remains the most perilous stage of drug development. Nowhere is this chasm wider than in neurodegeneration, where billions of dollars and years of research are lost when promising candidates fail in late-stage trials. The fundamental reason is often a stark divergence between the simplified environments of preclinical models and the complex, heterogeneous reality of human disease.
Featured
Search
De-Risking Synucleinopathy Therapeutics: A Human Tissue-First Framework for Target Validation
The transition from preclinical promise to clinical efficacy, the so-called "Translational Gap", remains the most perilous stage of drug development. Nowhere is this chasm wider than in neurodegeneration, where billions of dollars and years of research are lost when promising candidates fail in late-stage trials. The fundamental reason is often a stark divergence between the simplified environments of preclinical models and the complex, heterogeneous reality of human disease.
evadanielson55
Feb 24 min read
Validating CNS Therapeutics
Human Tissue Analysis in CNS drug development helps to bridge the translational gap and de-risk clinical development. New research on Alzheimers Disease, Palsy, Parkinsons, Multi System Atrophy and more offer insights into treatment development.
evadanielson55
Jan 274 min read
Our new innovative tissue staining platform turns complexity into simplicity
Offspring Biosciences is pleased to announce our expanded technical capacity with the purchase and installment of a Roche/Ventana Discovery Ultra tissue staining platform which significantly enhances our ability to deliver highly reliable, informative and 7-Plex Multiplex IHC & ISH Services | Preclinical CRO | Offspring Bioefficient support to our customers The Discovery Ultra platform allows for parallel and fully individualized processing of up to 30 slide-mounted tissue
-
Sep 16, 20211 min read
Offspring assist AstraZeneca with diabetes project aimed to validate a potential novel biomarker
In a recently published study in Plos One, a research team led by Dr Sara Hansson at AstraZeneca presented data which demonstrate that secretagogin, an intracellular calcium-binding intracellular protein highly enriched in pancreatic islets, may serve as biomarker in the blood for beta cell dysfunction in individuals with type 2 diabetes Offspring supported this project by performing multiplexed immunofluorescence-based detection of secretagogin selectively within the insulin
-
Sep 16, 20212 min read
bottom of page